- Home
- RDI vs DYAI Comparison
RDI vs DYAI Comparison
Compare RDI & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- DYAI
- Stock Information
- Founded
- RDI 1937
- DYAI 1979
- Country
- RDI United States
- DYAI United States
- Employees
- RDI N/A
- DYAI N/A
- Industry
- RDI Movies/Entertainment
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDI Consumer Discretionary
- DYAI Health Care
- Exchange
- RDI Nasdaq
- DYAI Nasdaq
- Market Cap
- RDI 30.1M
- DYAI 29.6M
- IPO Year
- RDI N/A
- DYAI 2004
- Fundamental
- Price
- RDI $1.36
- DYAI $0.91
- Analyst Decision
- RDI Hold
- DYAI Strong Buy
- Analyst Count
- RDI 1
- DYAI 1
- Target Price
- RDI $2.40
- DYAI $6.00
- AVG Volume (30 Days)
- RDI 31.5K
- DYAI 36.6K
- Earning Date
- RDI 08-13-2025
- DYAI 08-12-2025
- Dividend Yield
- RDI N/A
- DYAI N/A
- EPS Growth
- RDI N/A
- DYAI N/A
- EPS
- RDI N/A
- DYAI N/A
- Revenue
- RDI $205,644,000.00
- DYAI $3,554,344.00
- Revenue This Year
- RDI $7.47
- DYAI $22.56
- Revenue Next Year
- RDI $13.22
- DYAI $30.95
- P/E Ratio
- RDI N/A
- DYAI N/A
- Revenue Growth
- RDI N/A
- DYAI 57.59
- 52 Week Low
- RDI $1.17
- DYAI $0.91
- 52 Week High
- RDI $1.89
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- RDI 48.35
- DYAI 37.33
- Support Level
- RDI $1.38
- DYAI $0.95
- Resistance Level
- RDI $1.38
- DYAI $1.03
- Average True Range (ATR)
- RDI 0.06
- DYAI 0.07
- MACD
- RDI -0.01
- DYAI 0.00
- Stochastic Oscillator
- RDI 25.00
- DYAI 1.25
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.